(Q53354438)

13 May 2018

title

EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. (English)

1 reference

13 May 2018

1 reference

Chad A Livasy

1

1 reference

13 May 2018

F Catrina Reading

2

1 reference

13 May 2018

Dominic T Moore

3

1 reference

13 May 2018

John F Boggess

4

1 reference

13 May 2018

Ruth A Lininger

5

1 reference

13 May 2018

language of work or name

English

0 references

publication date

12 September 2005

1 reference

13 May 2018

published in

Gynecologic Oncology

1 reference

13 May 2018

volume

100

1 reference

13 May 2018

issue

1

1 reference

13 May 2018

page(s)

101-106

1 reference

13 May 2018

Analysis of clinicopathologic factors in malignant mixed Müllerian tumors of the uterine corpus

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Carcinosarcomas (Malignant Mullerian Mixed Tumors) of the Uterus and Ovary: A Genetic Study With Special Reference to Histogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Epidermal growth factor-related peptides and their receptors in human malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Epidermal growth factor receptors on human breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Different expression patterns of KIT, EGFR, and HER‐2 (c‐erbB‐2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Targeting epidermal growth factor receptor--are we missing the mark?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

ERBB-2 gene overexpression and amplification in uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

HER-2/neu amplification and overexpression in endometrial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.124

10.1016/J.YGYNO.2005.07.124

7 January 2021

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

16157366

1 reference

13 May 2018